Dexia AM recruits for team dedicated to health care sector


Dexia Asset Management (Dexia AM) has recruited Ward Capoen as senior analyst in charge of the biotechnology sector. Capoen, 33, has a doctorate in biotechnology from the university of Ghent, obtained in 2006, and has also earned an MBA from Vlerick Business School in Belgium, and has served an internship at Eli Lilly, one of the largest firms in the pharmaceuticals industry, a statement says. He will assist Rudi Van den Eynde, Head of Thematic Global Equity and manager of the Dexia Equities L Biotechnology fund, largely with the analysis of medical data concerning medications in testing and new treatments.